Zimmer Biomet (NYSE:ZBH) Stock Rating Upgraded by Zacks Research

Zimmer Biomet (NYSE:ZBH) was upgraded by investment analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research note issued to investors on Tuesday,Zacks.com reports.

A number of other equities analysts have also issued reports on the company. Sanford C. Bernstein increased their price target on Zimmer Biomet from $91.00 to $93.00 and gave the company a “market perform” rating in a research note on Thursday, August 6th. UBS Group reissued a “buy” rating and issued a $120.00 price objective on shares of Zimmer Biomet in a research note on Thursday, August 6th. Weiss Ratings upgraded Zimmer Biomet from a “sell (d+)” rating to a “hold (c-)” rating in a report on Tuesday, August 4th. Citizens Jmp decreased their target price on Zimmer Biomet from $120.00 to $105.00 and set a “market outperform” rating for the company in a research note on Wednesday, April 29th. Finally, Barclays lowered their target price on Zimmer Biomet from $100.00 to $94.00 and set an “underweight” rating on the stock in a report on Wednesday, April 29th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, fourteen have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $104.42.

Zimmer Biomet Trading Up 1.2%

Shares of NYSE:ZBH opened at $101.41 on Tuesday. The company has a 50 day moving average of $93.40 and a 200-day moving average of $91.31. The firm has a market cap of $19.34 billion, a P/E ratio of 24.67, a P/E/G ratio of 2.72 and a beta of 0.45. Zimmer Biomet has a twelve month low of $79.12 and a twelve month high of $107.85. The company has a current ratio of 1.69, a quick ratio of 0.94 and a debt-to-equity ratio of 0.50.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Wednesday, August 5th. The medical equipment provider reported $2.07 EPS for the quarter, beating analysts’ consensus estimates of $2.01 by $0.06. Zimmer Biomet had a net margin of 9.48% and a return on equity of 13.12%. The business had revenue of $2.18 billion for the quarter, compared to analyst estimates of $2.13 billion. During the same quarter last year, the business earned $2.07 earnings per share. The business’s revenue for the quarter was up 4.8% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. As a group, analysts anticipate that Zimmer Biomet will post 8.54 earnings per share for the current fiscal year.

Insider Activity at Zimmer Biomet

In other Zimmer Biomet news, insider Sang Yi sold 5,000 shares of the firm’s stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $82.64, for a total value of $413,200.00. Following the completion of the transaction, the insider directly owned 27,251 shares in the company, valued at $2,252,022.64. This trade represents a 15.50% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. 1.28% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Zimmer Biomet

Hedge funds have recently made changes to their positions in the company. DV Equities LLC purchased a new position in shares of Zimmer Biomet during the fourth quarter valued at $25,000. Tacita Capital Inc purchased a new stake in Zimmer Biomet in the 2nd quarter worth about $26,000. Ancora Advisors LLC purchased a new stake in Zimmer Biomet in the 2nd quarter worth about $29,000. Monetary Solutions Ltd acquired a new stake in Zimmer Biomet during the 4th quarter worth about $30,000. Finally, Gen Wealth Partners Inc acquired a new stake in Zimmer Biomet during the 4th quarter worth about $31,000. Hedge funds and other institutional investors own 88.89% of the company’s stock.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.